To hear about similar clinical trials, please enter your email below
Trial Title:
Telo Genomics Technology to Detect & Profile Multiple Myeloma MRD
NCT ID:
NCT05530096
Condition:
Multiple Myeloma
Conditions: Official terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Study type:
Observational [Patient Registry]
Overall status:
Not yet recruiting
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Diagnostic Test
Intervention name:
Standard of care
Description:
Participants will not receive any intervention in this study. Participants will receive
standard of care therapy
Arm group label:
MRD level group
Summary:
The purpose :
Detect and profile Multiple myeloma Measurable Residual Disease(MRD) prognostics for
monitoring post-transplant Multiple Myeloma (MM) Patients receiving maintenance therapy.
Criteria for eligibility:
Study pop:
Participant having confirmed Multiple Myeloma diagnosis will be enrolled in this study.
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- Confirmed MM diagnosis
- Transplant eligible patients in a first remission
- Known MRD level detected by ClonoSeq (other IMWG recognized methodologies can be
also employed)
- Availability of deidentified patient's demographic and clinical follow up data
- Receiving standard of care treatment
- Able to provide informed consent
Exclusion Criteria:
- Failure to meet inclusion criteria
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Start date:
January 2023
Completion date:
September 2028
Lead sponsor:
Agency:
Sir Mortimer B. Davis - Jewish General Hospital
Agency class:
Other
Source:
Sir Mortimer B. Davis - Jewish General Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05530096
